1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1630
  5. Art Unit 1635
  6. Examiner Mcleod

Examiner Mcleod Africa M

1635-MCLEOD-AFRICA-M

Employment Information

Art Unit:1635 — Drug, bio-affecting and body treating compositions
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
536 — Organic compounds -- part of the class 532-570 series
Phone:(703) 756-1907
Email:None
Location:None
Title:Pat Examnr (Biolgy)
Service:2 years
Grade:GS-11

Grant Rate and Difficulty Ranking

3-Year Grant rate: 0% over 2 cases
Difficulty: Not enough data to rank
Difficulty Percentile:

With Examiner Mcleod, you have a 0% chance of getting an issued patent by 3 years after the first office action.

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Mcleod, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1635

Examiner Mcleod's grant rate is lower than that of Art Unit 1635 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Mcleod 1.5
Art Unit 1635 1.6

Interview Benefit

Grant Rate without Interview

Examiner Mcleod has granted 0 of 2 cases without any applicant-requested interviews for a grant rate of 0%.

Grant Rate with Interview

Examiner Mcleod has granted 0 of 0 cases with at least one applicant-requested interview for a grant rate of 0%.

Interview Benefit

With Examiner Mcleod, conducting an interview increases your chance of getting a patent granted by 100%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17919198 Crispr-Inhibition For Facioscapulohumeral Muscular Dystrophy Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
17617891 Counter-Selection By Inhibition Of Conditionally Essential Genes Abandoned View
17933015 Improved Methods For Modification Of Target Nucleic Acids Abandoned View
17816049 Systems And Methods For High Yielding Recombinant Microorganisms And Uses Thereof Abandoned View
17719236 Methods And Compositions For Production Of Genetically Modified Primary Cells Abandoned View
17372676 Apolipoprotein C3 (Apoc3) Irna Compositions And Methods Of Use Thereof Patented View
17904282 Disseminated Neoplasia Cells And Methods Of Their Use To Control Invasive Or Pest Species Abandoned View
17719123 Recombinant Herpesvirus Of Turkeys (Hvt) And Preparation Method And Use Thereof Patented View
17602244 Multiplex Shrna For Use In Vectors Patented View
17533379 Engineered Cas-Transposon System For Programmable And Site-Directed Dna Transpositions Abandoned View
17768305 Rna Editor-Enhanced Rna Trans-Splicing Abandoned View
17622355 Cells Engineered For Oligonucleotide Delivery, And Methods For Making And Using Thereof Abandoned View
17611962 Optimized Genetic Tool For Modifying Bacteria Patented View
17634461 Novel Crispr Dna Targeting Enzymes And Systems Abandoned View
17572321 Oligonucleotide Therapy For Stargardt Disease Abandoned View
17624439 Crispr Type V-U1 System From Mycobacterium Mucogenicum And Uses Thereof Abandoned View
17815621 Three-Component Crispr/cas Complex System And Uses Thereof Patented View
17299660 Neurofilament Protein For Guiding Therapeutic Intervention In Amyotrophic Lateral Sclerosis Patented View
17486758 Compositions And Methods For Ttr Gene Editing And Treating Attr Amyloidosis Comprising A Corticosteroid Or Use Thereof Abandoned View
17603918 Methods And Compositions For Editing Rnas Abandoned View
17441466 Bifunctional Vectors Allowing Bcl11a Silencing And Expression Of An Anti-Sickling Hbb And Uses Thereof For Gene Therapy Of B-Hemoglobinopathies Abandoned View
17618100 Methods For Treating Muscular Dystrophy Abandoned View
17432858 Optimal Ps Modification Pattern For Heteronucleic Acids Abandoned View
17310660 An Anthracis Transcription Factor Csatf1 And The Application Thereof Abandoned View
17438543 High-Precision Base Editors Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.